Chronic hepatitis B treatment and monitoring

01OverviewDefinition, clinical context and the essential points that orientate the chapter.

The aim of chronic HBV treatment is to prevent cirrhosis, decompensation, HCC and transmission by maintaining viral suppression and reducing inflammation. HBsAg loss is the best functional endpoint but uncommon with current oral therapy. Treatment is straightforward in cirrhosis: detectable HBV DNA generally warrants antiviral therapy because even low-level replication can drive decompensation. In non-cirrhotic disease, quantitative DNA, repeated ALT, HBeAg state and fibrosis identify active hepatitis, while age, family history of HCC, comorbidity, pregnancy plans, extrahepatic disease and immunosuppression modify the threshold. A normal ALT at one visit is not a lifetime non-treatment decision.

First-line oral agents need potent antiviral activity and a high barrier to resistance. NICE recommends entecavir or tenofovir disoproxil in defined adult pathways, with peginterferon alfa considered for carefully selected compensated disease where a finite course and the probability of response justify toxicity. Entecavir dosing changes with previous lamivudine resistance, decompensation and renal impairment. Tenofovir disoproxil requires renal and bone risk assessment. HIV must be excluded or managed with an HIV specialist because HBV monotherapy can compromise future antiretroviral options. Decompensated disease belongs in a transplant-linked service; interferon is unsafe there.

Monitoring asks four different questions: is HBV DNA suppressed, is hepatic inflammation settling, is the medicine harming kidneys or bone, and does the person remain at risk of HCC or decompensation? Virological breakthrough should trigger an adherence and dispensing review before resistance is assumed. Stopping rules depend on drug, cirrhosis, antigen state and specialist protocol; sudden cessation can cause severe flare. Patients not currently treated still need scheduled ALT, DNA and fibrosis review because HBeAg-negative disease fluctuates. Household and sexual contacts should be tested and vaccinated, and every new immunosuppressive or pregnancy context should prompt proactive specialist planning.

Key points

Treat all adults with cirrhosis and detectable HBV DNA according to NICE, regardless of HBeAg status or ALT activity.
Without cirrhosis, treatment decisions integrate HBV DNA, serial ALT, fibrosis, age, family history, extrahepatic disease and future immunosuppression.
Entecavir and tenofovir disoproxil are potent oral options with high resistance barriers when used correctly; renal, bone and resistance context shapes selection.
Tenofovir alafenamide or other alternatives may be commissioned for selected patients through current specialist pathways, so do not substitute from an outdated algorithm.
Check HIV status before HBV monotherapy because entecavir or a single HBV-active nucleotide can select HIV resistance in untreated coinfection.
Nucleos(t)ide analogues suppress replication but seldom eradicate intrahepatic viral templates, making treatment long term for many patients.
Treatment does not abolish HCC risk; continue six-monthly surveillance whenever cirrhosis or NICE HBV risk criteria indicate it.
Adherence and uninterrupted supply are safety-critical because virological rebound may cause a severe flare, especially in cirrhosis or pregnancy-related stopping.

02AetiologyUnderlying causes, associations and risk factors, with why each one matters.

Perinatal and early-childhood acquisition

Transmission from an infected mother or during early childhood carries a high probability of persistence because immune clearance is less effective.

Sexual and blood exposure

Unprotected sexual contact, shared injecting equipment, needlestick injury and inadequately screened or sterilised procedures can transmit hepatitis B.

Household exposure

Contact with infected blood through shared razors, toothbrushes or open skin lesions can transmit virus, whereas ordinary social contact does not.

03PathophysiologyThe causal sequence from the underlying abnormality to symptoms and harm.

1
Persistent viral template
Covalently closed circular HBV DNA remains within hepatocyte nuclei, allowing viral replication to persist despite apparent biochemical quiescence or treatment suppression.
2
Immune-mediated hepatocyte injury
Liver damage arises mainly from the host immune response against infected hepatocytes rather than a simple direct cytopathic viral effect.
3
Fluctuating disease phases
Viral replication and immune activity change over time, so HBeAg, HBV DNA and ALT patterns can move between low-activity and inflammatory phases.
4
Fibrosis and oncogenesis
Repeated inflammation promotes fibrosis and cirrhosis, while viral DNA integration and clonal change contribute to hepatocellular carcinoma risk independently of cirrhosis.

04Clinical features and red flagsSymptoms, examination findings, patterns of presentation and time-critical warnings.

Treatment-eligible cirrhosis

Cirrhosis with any detectable HBV DNA is a high-risk state even if ALT is normal, symptoms are absent and HBeAg is negative.

Active non-cirrhotic hepatitis

Persistently raised ALT with meaningful viraemia and evidence of necroinflammation or fibrosis supports treatment after excluding metabolic, alcohol-related, drug and coinfection contributors.

Decompensated diseaseRed flag

Ascites, encephalopathy, variceal bleeding, jaundice or impaired synthetic function requires urgent antiviral and transplant-centre coordination; do not offer peginterferon in this setting.

Virological breakthrough

A confirmed rise in HBV DNA during therapy most commonly raises adherence, interrupted supply, wrong dosing or interaction questions before genuine antiviral resistance is concluded.

Tenofovir toxicity risk

CKD, proteinuria, hypophosphataemia, osteoporosis, fragility fracture, low body weight or concurrent nephrotoxins makes renal and bone assessment central to agent selection.

Treatment withdrawal flareRed flag

New malaise, jaundice or a sharp ALT and DNA rise after stopping therapy can become life-threatening, particularly with cirrhosis, and requires same-day review.

05InvestigationsWhat to request, why it matters and how to interpret it.

Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

01
Quantitative HBV DNA and ALT trendFirst step
Why
Define viral activity, treatment indication and virological response over time.
Interpretation and limitations
Use serial values and logarithmic change. Suppressed DNA indicates antiviral effect; confirmed rebound requires adherence and resistance assessment, while ALT can rise from other liver injury.
02
Fibrosis and cirrhosis assessment
Why
Identify people requiring treatment, HCC surveillance, portal-hypertension care or transplant referral.
Interpretation and limitations
Combine elastography or validated non-invasive tests with platelets, imaging and clinical findings. Inflammation can transiently elevate liver stiffness, and biopsy is reserved for unresolved treatment-relevant questions.
03
HBeAg, anti-HBe and quantitative HBsAg
Why
Characterise phenotype and monitor selected serological endpoints, especially with interferon strategies.
Interpretation and limitations
Seroconversion can be favourable but does not prove eradication. HBeAg-negative disease may remain active; HBsAg loss is the strongest functional endpoint but HCC risk can persist after cirrhosis.
04
Renal function, phosphate and urinalysis
Why
Establish baseline and detect nucleotide-associated renal tubular injury or CKD progression.
Interpretation and limitations
Use estimated renal function and risk-based urine protein or glucose and phosphate. A decline requires prompt specialist review of dose, agent and competing causes rather than abrupt unsupervised cessation.
05
HIV, HCV and HDV testing
Why
Identify coinfection that changes antiviral choice, prognosis and monitoring.
Interpretation and limitations
Treat HIV/HBV with a fully suppressive HIV regimen containing appropriate HBV-active agents; do not use entecavir or tenofovir as isolated HIV therapy. Confirm active HDV with RNA where indicated.
06
Ultrasound with or without AFP
Why
Surveil for HCC in cirrhosis and other NICE-defined chronic HBV risk groups.
Interpretation and limitations
Repeat every six months when indicated despite complete DNA suppression. A new lesion follows the diagnostic liver-imaging pathway; AFP cannot substitute for ultrasound.

06Differential diagnosisRealistic alternatives and the features that help distinguish them.

Acute hepatitis B

Recent exposure, compatible symptoms and evolving serology suggest acute infection; chronic infection requires persistent HBsAg or an established chronic pattern.

Resolved previous infection

HBsAg negativity with anti-HBc and usually anti-HBs indicates previous exposure without current surface-antigen-positive chronic infection, while reactivation risk can remain.

Occult hepatitis B

HBV DNA can rarely persist when HBsAg is undetectable, particularly during immunosuppression or in people with isolated anti-HBc.

Alternative chronic liver injury

Alcohol, metabolic steatotic disease, hepatitis C, autoimmune disease and hepatotoxic medicines can explain raised ALT alone or coexist with HBV.

07ManagementImmediate care, first-line treatment, alternatives and escalation.

01SelectDecide who needs treatmentFirst stepChronic HBV is confirmed and baseline DNA, ALT and fibrosis results are available.

1Treat cirrhosis with detectable HBV DNA through specialist care, and urgently link decompensated disease to a transplant service while correcting other complications.
2For non-cirrhotic disease, integrate serial DNA and ALT with fibrosis, age, HBeAg status, family HCC history, extrahepatic disease and planned immunosuppression rather than using one result.
3Check renal and bone risk, HIV status, previous antiviral exposure, pregnancy plans and likely adherence before agreeing oral therapy or a selected finite peginterferon strategy.

02SuppressStart oral antiviral safelyThe specialist team has selected entecavir, tenofovir disoproxil or another commissioned high-barrier option.

1Prescribe the exact product and renal-adjusted dose from the current SmPC, document previous lamivudine or HIV therapy and supply continuity, and explain that missed treatment can trigger rebound.
2Measure HBV DNA, ALT, renal safety markers and antigen status at NICE-defined early review points, then tailor longer-term frequency to response, cirrhosis and toxicity risk.
3If DNA rises, confirm the result and review adherence, dispensing gaps, food requirements, renal dosing and interactions before ordering resistance tests or adding or changing therapy.

03SustainMonitor treated and untreated diseaseViral suppression is achieved, or specialist review has concluded that immediate treatment is not currently indicated.

1Continue scheduled ALT, DNA, fibrosis and liver-reserve review because disease phase, renal function and life circumstances change, and give a route for earlier review after symptoms or immunosuppression plans.
2Maintain HCC surveillance and cirrhosis care when indicated, vaccinate susceptible contacts and address alcohol, metabolic risk, medicines, pregnancy and transmission without stigma.
3Do not stop nucleos(t)ide therapy unless a specialist stopping criterion and intensive post-withdrawal monitoring plan are documented, with rapid access for biochemical flare.

Key medicines and prescribing safety2 treatments · regimens, roles and cautions

Potent high-barrier nucleoside analogue for long-term HBV suppression in selected compensated or decompensated chronic infection.

Entecavir

For nucleoside-naive adults with compensated disease, 0.5 mg once daily with or without food; use 1 mg once daily on an empty stomach in lamivudine-refractory or decompensated contexts, with renal adjustment and specialist confirmation.

Confirm HIV status and previous lamivudine resistance, adjust for renal impairment and monitor for rebound after withdrawal. Lactic acidosis and severe hepatomegaly with steatosis are rare concerns; decompensated patients need close specialist monitoring.

Potent nucleotide analogue used for chronic HBV suppression, including selected resistant and decompensated disease, with a high barrier to resistance.

Tenofovir disoproxil 245 mg tablets

The licensed adult tablet dose is 245 mg once daily with food; apply the current SmPC renal restrictions or interval adjustment and specialist HBV or HIV plan rather than extrapolating this dose to every patient.

Assess renal and bone risk, monitor kidney function and phosphate, and avoid unreviewed nephrotoxic combinations. Confirm HIV status and never use isolated HBV dosing as inadequate HIV treatment; abrupt withdrawal can cause severe hepatitis flare.

08ComplicationsImportant consequences, why they occur and why they matter clinically.

Progressive fibrosis and cirrhosis

Repeated inflammatory activity deposits scar, distorts hepatic architecture and creates portal hypertension even after long clinically silent periods.

Hepatic decompensation

Advanced disease can present with ascites, variceal bleeding, encephalopathy, jaundice or acute-on-chronic liver failure, particularly during a viral flare.

Hepatocellular carcinoma

Cancer risk persists in cirrhosis and selected non-cirrhotic HBV populations, and viral suppression reduces but does not abolish that risk.

Extrahepatic immune disease

Immune-complex injury can cause polyarteritis nodosa, glomerulonephritis and other extrahepatic manifestations alongside or without prominent hepatic symptoms.

Reactivation and severe flare

Immunosuppression or abrupt antiviral withdrawal can trigger renewed replication, hepatitis, hepatic failure and preventable transmission to susceptible contacts.

09Monitoring and follow-upTreatment response, safety checks and longer-term review.

Check HBV DNA, ALT, liver reserve and relevant antigen status at the early treatment intervals in NICE guidance, then continue risk-adjusted specialist follow-up.
For tenofovir disoproxil, monitor estimated renal function and risk-based phosphate and urinalysis; assess bone health when fracture or osteoporosis risk is material.
For entecavir, monitor renal function for dose adjustment and scrutinise virological response particularly after previous lamivudine resistance.
Continue six-monthly HCC ultrasound surveillance where cirrhosis or NICE HBV risk criteria apply, irrespective of an undetectable HBV DNA result.
After any specialist-approved cessation, monitor ALT and HBV DNA closely for relapse or flare for the full protocol period and give same-day jaundice advice.
For untreated chronic infection, schedule repeated ALT, DNA and fibrosis review rather than issuing indefinite discharge after a single inactive profile.

10Special situationsVariants, exceptions and circumstances that change the usual approach.

Suppression is prevention

Sustained HBV DNA suppression lowers inflammation, fibrosis progression, decompensation and HCC risk, but it does not remove every viral template or all cancer risk.

Cirrhosis lowers threshold

Because small amounts of viral activity can destabilise advanced disease, detectable DNA in cirrhosis warrants treatment even when ALT and HBeAg appear reassuring.

Breakthrough needs chronology

Before invoking resistance, reconstruct dose taking, pharmacy supply, renal adjustments and interacting medicines; an avoidable gap is both common and correctable.

Coinfection changes the unit

In HIV/HBV, the relevant prescription is a complete suppressive HIV regimen containing appropriate HBV-active drugs, not an HBV tablet considered in isolation.

Monitoring outlives treatment choice

Even excellent viral suppression does not replace fibrosis, renal and HCC surveillance, while untreated inactive disease can later reactivate and require therapy.

11Common pitfallsFrequent interpretation and management errors.

01
Deferring treatment in cirrhosis because ALT is normal or HBV DNA is only just detectable.
02
Starting HBV monotherapy without knowing HIV status and the patient's prior antiviral history.
03
Choosing tenofovir disoproxil without baseline renal, phosphate and bone-risk assessment.
04
Calling a DNA rise resistance before verifying adherence, dispensing continuity and correct renal dosing.
05
Stopping long-term oral treatment abruptly after one undetectable DNA result.
06
Discontinuing HCC surveillance because antiviral therapy has achieved sustained virological suppression.